Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV003336589 | SCV004046597 | uncertain significance | Bardet-Biedl syndrome 13; Meckel syndrome, type 1; Joubert syndrome 28 | 2022-11-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003358166 | SCV004077286 | uncertain significance | Inborn genetic diseases | 2023-06-22 | criteria provided, single submitter | clinical testing | The c.1447A>C (p.T483P) alteration is located in exon 16 (coding exon 16) of the MKS1 gene. This alteration results from a A to C substitution at nucleotide position 1447, causing the threonine (T) at amino acid position 483 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV003336589 | SCV005649610 | uncertain significance | Bardet-Biedl syndrome 13; Meckel syndrome, type 1; Joubert syndrome 28 | 2024-03-27 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004733616 | SCV005365721 | uncertain significance | MKS1-related disorder | 2024-01-17 | no assertion criteria provided | clinical testing | The MKS1 c.1447A>C variant is predicted to result in the amino acid substitution p.Thr483Pro. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0065% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |